Panel: Investing Beyond IO Set To Heat Up
Executive Summary
Panelists at the World Medical Innovation Forum discussed the new opportunities they are looking at and where the money will be going in the future.
You may also be interested in...
Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs
Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.
Video: Chris Viehbacher Interviewed At BioPharm America
Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies.
Viehbacher surfaces at $2bn Bertarelli fund
Christopher Viehbacher, ex-CEO of Sanofi, has been appointed as the managing partner of Waypoint Capital's US-based fund, Gurnet Point Capital. Waypoint is the investment vehicle of the Bertarelli family, former owners of Serono, which was sold to Merck KGaA of Germany in 2007 in a deal worth around €10bn. Waypoint's chairman is Ernesto Bertarelli, the former CEO of Serono.